Related Experiment Video
Updated: May 14, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Management of cardiovascular disease in patients with kidney disease
Mark R Kahn1, Michael J Robbins, Michael C Kim
1Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, PO Box 1030, New York, NY 10029-6574, USA. mark.kahn@ mountsinai.org
Insights
Cardiovascular disease is a major concern for patients with chronic kidney disease. This review covers the epidemiology, pathophysiology, diagnosis, and treatment of heart conditions in kidney disease patients.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular disease (CVD) poses a significant burden on patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD).
- Kidney dysfunction exacerbates CVD through accelerated atherosclerosis, valvular disease, heart failure, and pericardial disease.
- Shared risk factors, systemic inflammation, and vascular calcification contribute to this comorbidity.
Purpose of the Study:
- To review the epidemiology, pathophysiology, and diagnosis of CVD in patients with kidney disease.
- To propose evidence-based recommendations for pharmacological and surgical treatment of CVD in this population.
Main Methods:
- Review of existing literature on cardiovascular disease in kidney disease.
- Analysis of epidemiological data, pathophysiological mechanisms, and diagnostic challenges.
- Synthesis of current therapeutic strategies and clinical trial data.
Main Results:
- Kidney dysfunction significantly impacts cardiovascular health, increasing CVD risk and complicating diagnosis and treatment.
- Noninvasive testing and pharmacotherapeutic strategies may have reduced efficacy in patients with severe kidney disease.
- Exclusion of CKD patients from trials creates therapeutic uncertainties.
Conclusions:
- Effective management of CVD in kidney disease requires understanding unique pathophysiological mechanisms.
- Tailored, evidence-based recommendations are crucial for optimizing pharmacological and surgical interventions.
- Further research is needed to address therapeutic uncertainties in this vulnerable population.
Abstract:
The burden of cardiovascular disease is high in patients with chronic kidney disease or end-stage renal disease. The presence of kidney dysfunction affects the cardiovascular system in multiple ways, including accelerated progression of atherosclerosis and valvular disease, the exacerbation of congestive heart failure, and the development of pericardial disease. This comorbidity results not only from the concordance of shared risk factors, but also from other issues specific to this population, such as systemic inflammation and vascular calcification. Furthermore, both the sensitivity and specificity of noninvasive testing modalities, and the efficacy of several pharmacotherapeutic strategies, are diminished in this population. The exclusion of patients with severe kidney disease from many clinical trials of cardiac interventions raises various therapeutic uncertainties, and kidney disease itself is likely to alter the underlying cardiovascular physiology. In this Review, we discuss aspects of the epidemiology, pathophysiology, and diagnosis of cardiovascular disease in patients with kidney disease, and propose specific, evidence-based recommendations for pharmacological and surgical treatment.
Related Concept Videos
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Heart Failure Drugs: Diuretics
Acute Kidney Injury V: Interprofessional Care
Heart Failure V: Medical Management
